Your browser is no longer supported. Please, upgrade your browser.
Settings
OCUL Ocular Therapeutix, Inc. daily Stock Chart
OCUL [NASD]
Ocular Therapeutix, Inc.
Index- P/E- EPS (ttm)-1.59 Insider Own0.30% Shs Outstand41.20M Perf Week4.20%
Market Cap153.26M Forward P/E- EPS next Y-1.32 Insider Trans86.71% Shs Float35.91M Perf Month-5.58%
Income-55.70M PEG- EPS next Q-0.38 Inst Own52.50% Short Float15.80% Perf Quarter-30.34%
Sales2.00M P/S76.63 EPS this Y-22.10% Inst Trans-1.26% Short Ratio10.48 Perf Half Y-38.00%
Book/sh1.17 P/B3.18 EPS next Y13.20% ROA-81.60% Target Price14.43 Perf Year-24.24%
Cash/sh- P/C- EPS next 5Y- ROE-133.70% 52W Range3.46 - 8.28 Perf YTD-6.53%
Dividend- P/FCF- EPS past 5Y-26.20% ROI-140.40% 52W High-55.06% Beta1.78
Dividend %- Quick Ratio4.30 Sales past 5Y186.30% Gross Margin76.60% 52W Low7.51% ATR0.17
Employees119 Current Ratio4.30 Sales Q/Q0.00% Oper. Margin- RSI (14)42.51 Volatility4.31% 4.66%
OptionableYes Debt/Eq0.31 EPS Q/Q28.10% Profit Margin- Rel Volume0.79 Prev Close3.70
ShortableYes LT Debt/Eq0.18 EarningsMar 07 AMC Payout- Avg Volume541.36K Price3.72
Recom1.70 SMA200.35% SMA50-11.55% SMA200-35.97% Volume428,792 Change0.54%
Dec-03-18Reiterated Cantor Fitzgerald Overweight $22 → $24
Nov-15-18Initiated Raymond James Strong Buy $10
Sep-07-18Initiated Piper Jaffray Overweight
Oct-24-17Initiated Guggenheim Buy $12
Jul-26-17Initiated H.C. Wainwright Buy $10
Jul-12-17Reiterated Cantor Fitzgerald Overweight $35 → $21
Jun-23-17Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-10-17Initiated Cantor Fitzgerald Overweight $35
Nov-15-16Reiterated RBC Capital Mkts Outperform $30 → $32
Aug-11-16Initiated JMP Securities Mkt Outperform
Feb-17-16Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-13-15Initiated Morgan Stanley Overweight $24
Aug-05-15Initiated Nomura Buy $46
Apr-08-15Reiterated RBC Capital Mkts Outperform $50 → $48
Mar-11-15Reiterated RBC Capital Mkts Outperform $35 → $50
Mar-11-15Reiterated Oppenheimer Outperform $42 → $49
Jan-30-15Reiterated Oppenheimer Outperform $25 → $42
Feb-20-19 08:30AM  Ocular Therapeutix Announces Dosing of First Patient in OTX-TKI (tyrosine kinase inhibitor implant) Phase 1 Clinical Trial for the Treatment of Wet Age-related Macular Degeneration (AMD) Business Wire
Feb-06-19 12:30PM  Is Ocular Therapeutix, Inc. (NASDAQ:OCUL) A Financially Sound Company? Simply Wall St.
Jan-22-19 07:40AM  Detailed Research: Economic Perspectives on Inovalon, Merit Medical, Senseonics, Ocular Therapeutix, The Hartford Financial Services Group, and Synopsys What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jan-11-19 10:32AM  Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza Zacks
08:38AM  The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA Benzinga
Jan-10-19 04:01PM  Ocular Therapeutix Submits Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery Business Wire
Jan-07-19 09:00AM  Purdue Pharma L.P. and Ocular Therapeutix, Inc. Announce Initiation of Collaborative Research Activities to Evaluate Innovative Formulations for Non-Opioid Treatments for Pain Business Wire
Dec-28-18 08:00AM  Ocular Therapeutix Announces Completion of Debt Refinancing Business Wire +6.72%
Dec-26-18 10:56AM  Edited Transcript of OCUL earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Dec-20-18 11:00AM  Are Insiders Buying Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock? Simply Wall St.
08:00AM  Ocular Therapeutix Added to Nasdaq Biotechnology Index Business Wire
Dec-06-18 08:00AM  Ocular Therapeutix Announces the Hiring of Chad Brines, Vice President, Sales Business Wire +8.20%
Dec-04-18 08:59AM  Options Traders Expect Huge Moves in Ocular Therapeutix (OCUL) Stock Zacks
Dec-03-18 08:23AM  CORRECTING and REPLACING Ocular Therapeutix Announces FDA Approval of DEXTENZA® for the Treatment of Ocular Pain Following Ophthalmic Surgery Business Wire -13.96%
Nov-21-18 08:00AM  Ocular Therapeutix to Present at the 30th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-15-18 06:35PM  H.C. Wainwright Sees over 80% Upside Potential for These Three Biotech Stocks SmarterAnalyst +5.95%
Nov-12-18 07:40AM  Recent Analysis Shows Clovis Oncology, Evertec, Etsy, Ring Energy, Ocular Therapeutix, and Destination Maternity Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-07-18 06:35PM  Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates Zacks
05:36PM  Ocular Therapeutix: 3Q Earnings Snapshot Associated Press
04:01PM  Ocular Therapeutix Reports Third Quarter 2018 Financial Results and Business Update Business Wire
Oct-31-18 08:00AM  Ocular Therapeutix To Report Third Quarter 2018 Financial Results Business Wire
Oct-30-18 10:33AM  Will Ocular Therapeutix (OCUL) Report Negative Earnings Next Week? What You Should Know Zacks -5.08%
Oct-22-18 02:54PM  Ocular Therapeutix (OCUL): ReSure Warning Letter Insignificant to Pipeline, Says Analyst SmarterAnalyst
Oct-19-18 08:09AM  Ocular Therapeutix stock drops 10% after FDA warning letter MarketWatch
07:50AM  Ocular Therapeutix Receives FDA Warning Letter Related to ReSure® Sealant Business Wire
Oct-18-18 08:55AM  Investor Expectations to Drive Momentum within Teradata, Liberty TripAdvisor, CPI Card Group, Cara Therapeutics, Ocular Therapeutix, and G-III Apparel Group, LTD Discovering Underlying Factors of Influence GlobeNewswire
Oct-11-18 12:57PM  Who Owns Ocular Therapeutix Inc (NASDAQ:OCUL)? Simply Wall St.
Oct-10-18 04:26PM  Why Analysts See Solid Upside Potential for Ocular Therapeutix (OCUL), Catalyst Pharmaceuticals (CPRX), and AcelRx (ACRX) SmarterAnalyst -5.62%
Sep-26-18 08:00AM  Ocular Therapeutix to Present at the 2018 Cantor Global Healthcare Conference Business Wire
Sep-11-18 10:11AM  Edited Transcript of OCUL earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Sep-10-18 12:36PM  Here's Why Ocular Therapeutix Jumped 21.6% in August Motley Fool
Aug-29-18 08:00AM  Ocular Therapeutix to Present at the H.C. Wainwright 20th Annual Global Investment Conference Business Wire
Aug-27-18 08:30AM  Factors of Influence in 2018, Key Indicators and Opportunity within Lindblad Expeditions, Milacron, Lantheus, RCI Hospitality, Ingles Markets, and Ocular Therapeutix New Research Emphasizes Economic Growth GlobeNewswire
Aug-21-18 07:15PM  Ocular Therapeutix Inc (OCUL) President & CEO Antony C. Mattessich Bought $119,000 of Shares GuruFocus.com
Aug-20-18 01:00PM  JMP Highlights Two Biotech Stocks to Consider Ahead of Upcoming FDA Decisions: Trevena (TRVN), Ocular (OCUL) SmarterAnalyst
Aug-07-18 05:20PM  Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:17PM  Ocular Therapeutix: 2Q Earnings Snapshot Associated Press
04:00PM  Ocular Therapeutix Reports Second Quarter 2018 Financial Results and Business Update Business Wire
Jul-31-18 04:00PM  Ocular Therapeutix To Report Second Quarter 2018 Financial Results Business Wire
Jul-19-18 08:00AM  Ocular Therapeutix Announces FDA Acceptance of NDA Resubmission for DEXTENZA® Business Wire
05:53AM  Ocular Therapeutix Sees Hammer Chart Pattern: Time to Buy? Zacks
Jul-18-18 07:26AM  Ocular Therapeutix (OCUL) Enters Oversold Territory Zacks
Jun-29-18 08:00AM  Ocular Therapeutix Announces NDA Resubmission of DEXTENZA Business Wire -6.90%
Jun-22-18 07:55AM  Report: Developing Opportunities within Mercantile Bank, Kindred Healthcare, Ocular Therapeutix, Roper Technologies, Milacron, and First Defiance Financial Future Expectations, Projections Moving into 2018 GlobeNewswire
Jun-12-18 08:00AM  Ocular Therapeutix to Present at the 2018 JMP Securities Life Sciences Conference Business Wire +6.34%
May-29-18 10:24AM  5 Clinical-Stage Biotech Stocks to Buy Under $10 InvestorPlace
May-14-18 09:52PM  Edited Transcript of OCUL earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-08-18 05:10PM  Ocular Therapeutix: 1Q Earnings Snapshot Associated Press
04:01PM  Ocular Therapeutix Reports First Quarter 2018 Financial Results and Business Update Business Wire
May-03-18 08:38AM  Ocular Therapeutix Announces Treatment of First Patient in Phase 1 Clinical Trial of OTX-TIC (travoprost intracameral implant) for the Treatment of Glaucoma and Ocular Hypertension Business Wire
07:45AM  Investor Expectations to Drive Momentum within Quaker Chemical, Ocular Therapeutix, Viad, Ingredion, LivePerson, and Tableau Software Discovering Underlying Factors of Influence GlobeNewswire
Apr-27-18 08:00AM  Ocular Therapeutix to Present Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Business Wire
Apr-26-18 04:01PM  Ocular Therapeutix to Report First Quarter 2018 Financial Results Business Wire
Apr-09-18 04:30PM  Ocular Therapeutix to Present Data at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium Business Wire
10:29AM  Biotechs Take the Lead This Morning TheStreet.com
Apr-03-18 03:11PM  Is There Now An Opportunity In Ocular Therapeutix Inc (NASDAQ:OCUL)? Simply Wall St.
Mar-22-18 04:36PM  Ocular Therapeutix To Present at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018 Business Wire
06:40AM  Can the Rally in Ocular Therapeutix (OCUL) Shares Continue? Zacks
Mar-16-18 01:11AM  Edited Transcript of OCUL earnings conference call or presentation 8-Mar-18 1:30pm GMT Thomson Reuters StreetEvents +9.94%
Mar-15-18 08:30PM  Ocular Therapeutix Inc (NASDAQ:OCUL): Are Analysts Optimistic? Simply Wall St.
Mar-09-18 08:20AM  Report: Exploring Fundamental Drivers Behind Cenovus Energy, Depomed, Zoe's Kitchen, NetApp, Keryx Biopharmaceuticals, and Ocular Therapeutix New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-08-18 01:00PM  Under SEC scrutiny, Bedfords Ocular Therapeutix plans FDA do-over American City Business Journals
09:23AM  Ocular Therapeutix reports 4Q loss Associated Press
07:30AM  Ocular Therapeutix Reports Fourth Quarter and Year End 2017 Financial Results and Business Update Business Wire
06:35AM  Want To Invest In Ocular Therapeutix Inc (NASDAQ:OCUL)? Heres How It Performed Lately Simply Wall St.
Feb-28-18 08:00AM  Ocular Therapeutix to Present at the Cowen and Company 38th Annual Health Care Conference Business Wire
Feb-27-18 04:00PM  Ocular Therapeutix To Report Fourth Quarter 2017 Financial Results Business Wire
Feb-21-18 08:02AM  Top 3 Stocks Insiders Are Buying Simply Wall St. +5.85%
Feb-08-18 08:00AM  Ocular Therapeutix to Participate in the 2018 Glaucoma 360 Meeting in San Francisco Business Wire
Jan-29-18 04:01PM  Ocular TherapeutixTM Announces Closing of Public Offering of Common Stock Business Wire +6.91%
Jan-25-18 09:11AM  Benzinga Pro's 4 Stocks To Watch Today Benzinga -14.22%
09:09AM  Ocular TherapeutixTM Announces Pricing of Public Offering of Common Stock Business Wire
Jan-24-18 04:01PM  Ocular Therapeutix Announces Proposed Public Offering of Common Stock Business Wire
Jan-08-18 08:20AM  New Research Coverage Highlights TTM Technologies, LogMeIn, Ocular Therapeutix, Everbridge, Power Integrations, and CBIZ Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
08:00AM  Ocular Therapeutix Announces Kevin Hanley as Senior Vice President, Technical Operations and Naymisha Patel as Vice President of Quality Business Wire
Jan-01-18 09:15AM  Ocular Therapeutix, Inc. :OCUL-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018 Capital Cube
Dec-26-17 11:55AM  ETFs with exposure to Ocular Therapeutix, Inc. : December 26, 2017 Capital Cube
Dec-22-17 04:56PM  Ocular Therapeutix gets subpoena from SEC over eye pain drug Reuters
04:05PM  Ocular Therapeutix Provides Legal Update Business Wire
Dec-13-17 04:54PM  Is It Too Late To Buy Ocular Therapeutix Inc (NASDAQ:OCUL)? Simply Wall St. +9.84%
Dec-05-17 08:00AM  Ocular Therapeutix to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference Business Wire
Dec-04-17 12:00PM  Was Ocular Therapeutix Incs (OCUL) EPS Decline A Part Of Broader Industry Downturn? Simply Wall St.
Nov-20-17 08:03PM  Robbins Arroyo LLP Investigates the Officers and Directors of Ocular Therapeutix, Inc. (OCUL) on Behalf of Shareholders Business Wire -5.84%
Nov-13-17 04:05PM  Edited Transcript of OCUL earnings conference call or presentation 7-Nov-17 10:00pm GMT Thomson Reuters StreetEvents
Nov-07-17 05:25PM  Ocular Therapeutix reports 3Q loss Associated Press -6.06%
04:05PM  Ocular Therapeutix Reports Third Quarter 2017 Financial Results and Provides Corporate Update Business Wire
12:50PM  Ocular Therapeutix Inc to Host Earnings Call ACCESSWIRE
Oct-31-17 08:00AM  Ocular Therapeutix to Report Third Quarter 2017 Financial Results Business Wire
Oct-24-17 07:16PM  Robbins Arroyo LLP Is Investigating the Officers and Directors of Ocular Therapeutix, Inc. (OCUL) on Behalf of Shareholders Business Wire +5.73%
Oct-02-17 02:52PM  How Does Investing In Ocular Therapeutix Inc (OCUL) Impact Your Portfolio? Simply Wall St.
Sep-26-17 03:09PM  Robbins Arroyo LLP Is Investigating the Officers and Directors of Ocular Therapeutix, Inc. (OCUL) on Behalf of Shareholders Business Wire
Sep-25-17 08:00AM  Ocular Therapeutix Appoints Donald Notman as Chief Financial Officer Business Wire
Sep-13-17 11:55AM  Have Investors Already Priced In Ocular Therapeutix Incs (OCUL) Growth? Simply Wall St.
Sep-08-17 09:00AM  Ocular Therapeutix Appoints Michael Goldstein, M.D., M.B.A., as Chief Medical Officer Business Wire
Sep-06-17 04:05PM  Ocular Therapeutix to Present at Three Upcoming Investor Conferences Business Wire
Sep-05-17 10:35AM  OCUL DEADLINE TODAY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Ocular Therapeutix, Inc. and a Lead Plaintiff Deadline of September 5, 2017 ACCESSWIRE
10:33AM  FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline: September 5, 2017 ACCESSWIRE
Sep-02-17 09:30AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ocular Therapeutix, Inc. of Class Action Lawsuit and Upcoming Deadline - OCUL ACCESSWIRE
Sep-01-17 11:55PM  DEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
12:02PM  DEADLINE TUESDAY: The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Ocular Therapeutix, Inc. Shareholders and a Lead Plaintiff Deadline of September 5, 2017 (OCUL) ACCESSWIRE
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension. The company is also developing OTX-TIC, an intracameral travoprost implant for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; and OTX-TKI, a tyrosine kinase inhibitor intravitreal injection that delivers a hydrogel-based anti-angiogenic formulation for the treatment of wet age-related macular degeneration. In addition, it markets ReSure Sealant, a hydrogel-based ophthalmic wound sealant to seal corneal incisions following cataract surgery. Further, the company engages in the preclinical development of formulations of its hydrogel administered via intravitreal injection to address the diseases and conditions of the back of the eye. Ocular Therapeutix, Inc. has collaboration agreement with Regeneron Pharmaceuticals, Inc. for the development and commercialization of products using its hydrogel in combination with large molecule VEGF-targeting compounds for the treatment of retinal diseases. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hanley Kevin F.See RemarksDec 14Buy5.5010,00055,00020,000Dec 18 08:52 AM
Hanley Kevin F.SEE REMARKSDec 10Buy5.6010,00056,00010,000Dec 12 04:35 PM
Bollag Daniel MSee RemarksDec 06Buy5.7617,400100,22442,100Dec 10 04:15 PM
Mattessich Antony C.President & CEOAug 20Buy5.9520,000119,00057,900Aug 21 04:30 PM
Notman DonaldChief Financial OfficerAug 14Buy6.2912,50078,62517,300Aug 15 05:13 PM
Mattessich Antony C.President and CEOAug 10Buy6.2316,900105,28737,900Aug 13 04:43 PM